A 50-year-old man undergone total thyroidectomy and histopathology revealed papillary thyroid carcinoma with a tumor size of 4.5 cm. The patient was referred to a nuclear medicine clinic for radioiodine therapy. Since the thyroglobulin level before the treatment was 495 ug/L, low-dose (185 MBq) I-131 scan was performed. In addition to multiple liver metastases, bone metastases were detected in the sacrum and right 7 rib in I-131 whole body scanning and single photon emission computed tomography/computed tomography (CT) imaging at the time of initial staging. We present a case of multiple metastatic papillary thyroid carcinoma whose radioiodine treatment response and clinical outcome were evaluated with F-fluorodeoxyglucose and Gallium-68 FAPI-04 positron emission tomography/CT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950682 | PMC |
| http://dx.doi.org/10.4274/mirt.galenos.2022.02438 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.
Front Endocrinol (Lausanne)
December 2024
Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Fukushima, Japan.
Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disorder, accompanied by multiple endocrine neoplasms of the parathyroid, pancreas, pituitary, and other neoplasms in the adrenal glands. However, in some cases, patients clinically diagnosed with MEN1 may be genotype-negative.
Case Presentation: A 56-year-old female was diagnosed with MEN1 based on a macroprolactinoma (19 mm in diameter), primary hyperparathyroidism, and a cortisol-producing adrenal adenoma, without a family history.
CT-based radiomics features for the differential diagnosis of nodular goiter and papillary thyroid carcinoma: an analysis employing propensity score matching.
Front Oncol
December 2024
Medical Imaging Center, The first Affiliated Hospital of Jinan University, Guangzhou, China.
Purpose: This study aims to evaluate the effectiveness of CT-based radiomics features in discriminating between nodular goiter (NG) and papillary thyroid carcinoma (PTC).
Methods: A retrospective cohort comprising 228 patients with nodular goiter (NG) and 227 patients with papillary thyroid carcinoma (PTC) diagnosed between January 2018 and December 2022 was consecutively enrolled. Propensity score matching (PSM) was applied to align patients with NG and PTC.
YTHDF3-induced degradation of P4HA2 mRNA inhibits glycolysis in papillary thyroid cancer through Hippo signaling pathway.
Int J Biol Macromol
December 2024
Thyroid Surgery Department, Xiangya Hospital, Central South University, Changsha 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China. Electronic address:
Background: Prolyl-4-hydroxylase-A2 (P4HA2) is a pivotal enzyme involved in the regulation of tumorigenesis and progression. However, the precise biological roles and potential functions of P4HA2 in papillary thyroid cancer (PTC) remain poorly elucidated.
Methods: Gain-of-function and loss-of-function approaches were employed to investigate the underlying biological effects of P4HA2 on PTC cell proliferation and metastasis both in vitro and in vivo.
Does a Restrictive Diagnostic Work-up for Thyroid Nodules Lead to a Different Papillary Thyroid Cancer Patient Population? A Comparison Between Dutch and U.S. T1-T3 Patient Population.
World J Surg
December 2024
Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Introduction: The 2015 American Thyroid Association guidelines recommend de-escalating surgical treatment for papillary thyroid cancer (PTC). We hypothesize that the Dutch PTC population might differ due to a restrictive diagnostic policy that mainly selects symptomatic and palpable thyroid nodules for further diagnostics, potentially selecting relatively more aggressive tumors. We aimed to describe the Dutch PTC population because differences in populations can have consequences for the adoption of foreign guidelines.
View Article and Find Full Text PDFAlectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion.
Eur J Cancer
December 2024
Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy. Electronic address:
Background: Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs.
Methods: We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!